scPharmaceuticals to Present at Key Investor Conferences

Prime Highlights:

scPharmaceuticals to host three investor conferences in May 2025.
CEO John Tucker to host Citizens Life Sciences, H.C. Wainwright BioConnect, and Craig-Hallum presentations.

Key Facts:

Presentation dates set on May 7, 20, and 28, 2025.
Webcasts available on scPharmaceuticals’ Investor Relations site.

Key Background:

Massachusetts-founded scPharmaceuticals Inc. (NASDAQ: SCPH) is a biopharma company with an aim to advance cardiorenal care. scPharmaceuticals is committed to changing how treatments are being performed through patient-focused innovation development to tackle unmet medical demands of the cardiorenal segment. Its objective is to give integrated treatments that will aid better patient outcomes, especially for individuals who are battling chronic diseases such as heart failure and chronic kidney disease.

There has been recent news of diversifying its portfolio of products, such as when a supplemental New Drug Application (sNDA) for FUROSCIX received FDA approval. FUROSCIX has thus become approved to be used for the treatment of adult nephrotic syndrome, as well as edema of chronic kidney disease in adults. Diversification will enable more patients to receive the product by April 2025. The company’s cardiorenal care mission is healthier outcomes worldwide through new treatments and multi-disciplinary care.

Financially, scPharmaceuticals grew aggressively. In the fourth quarter of 2024, the company generated $12.2 million in net revenue for FUROSCIX®, year-to-date revenue to date at $36.3 million. As of 2024, the company held cash and cash equivalents of $75.7 million, available to invest in future growth in product development and expansion.

Going forward, scPharmaceuticals will be pipeline building and expanding its presence in the healthcare industry. scPharmaceuticals’ presence at near-term investor conferences during May 2025 will be an opportunity to address the investment community where CEO John Tucker will make the company statement of growth and strategy direction. It will be part of the continuing practice of transparency and closely working with its shareholders.